Clinical Activity Data

I am writing to request the following information under the Freedom of Information Act 2000:
For your adult eating disorder service from January 2025-November 2025 what were the BMI of inpatients and community patients with an eating disorder at the time they were discharged?

For your adult eating disorderservice in 2025 how many inpatients and communitypatients with an eating disorderwere discharged with a BMI ofunder 15?

For your Children’s eating disorder service what was the weight for height percentage of inpatientsand community patients with an eating disorder at the time they were discharged between January 2025 and November 2025?

For your Children’s eating disorder service in 2025 how many inpatients and community patients with an eating disorderwere discharged at a weight for height of less than 75 ?

At point of discharge if patientshad a BMI of under 15, or equivalent to weight for height ofless than 75, where were yourpatients discharged to between January 2025 and November 2025? (for both adults and children)

In your adult and children’s eatingdisorder service what treatment is offered to inpatient andcommunity patients who had a BMI of under 15, or equivalent to weight for height of less than 75 between January 2025 and November 2025?

Subject: Freedom of Information Request – Non-Pharmacological ADHD Interventions for Children

Dear FOI Officer,

I am writing to request information under the Freedom of Information Act 2000 regarding the provision of non-pharmacological interventions for children and young people with Attention Deficit Hyperactivity Disorder (ADHD) within your Trust. To help me understand your service model, I would be grateful if you could provide responses to the following:

1. Service Provision
• – Do you provide non-pharmacological interventions for children and young people diagnosed with ADHD?
• – If so, please list the types of interventions offered (e.g., parent training, CBT, psychoeducation, skills groups, school liaison, peer support, digital interventions, etc.).
• – Are these delivered by your Trust directly, jointly with external providers, or commissioned from other organisations?
• With what frequency are patients/families offered these sessions?
• How many sessions are offered to patients/families or at what point is intervention ceased?

2. Referral & Access
• – At what stage of the care pathway are non-pharmacological interventions offered (e.g., pre-diagnosis, post-diagnosis, alongside medication, instead of medication)?
• – What are the eligibility criteria (if any) for accessing these interventions?

3. Workforce & Delivery
• – Which professional groups deliver these interventions (e.g., psychologists, nurses, occupational therapists, social workers, peer support workers)?
How many WTE (whole time equivalent) staff are currently employed in delivering ADHD-related non-pharmacological interventions?

4. Capacity & Outcomes
• – Approximately how many children/young people accessed these interventions in the last financial year (April–March)?
• – Do you collect outcome measures for these interventions? If yes, please specify which tools or measures are used (e.g., SDQ, SNAP-IV, goal-based outcomes, parent/carer feedback, etc.).

5. Commissioning & Funding
• – Are these interventions funded within core CAMHS/neurodevelopmental services, or separately commissioned?
• – Has your Trust secured any additional funding streams (e.g., NHS Long Term Plan, local authority joint commissioning) to support delivery?

6. Future Planning
• – Are there plans to expand, reduce, or change the provision of non-pharmacological ADHD interventions for children in the next 2 years?

Notes

– Please provide the information in electronic format (Word, Excel, or PDF).
– If the information requested exceeds the cost/time limit, please advise which elements could be prioritised.
– If you do not hold the information, please confirm whether another organisation may be responsible.

Thank you for your assistance. I look forward to your response within the statutory 20 working days.

Dear Sir/Madam,

This is a Freedom of Information Act request. I would like to know the following information:
• How many children (under 18s) have been given the contraceptive implant for each of the last five calendar years (2021, 2022, 2023, 2024 and 2025 so far)?
• Please provide a breakdown by age of all children given the contraceptive implant for each of the last five calendar years (2021, 2022, 2023, 2024 and 2025 so far).
• Please consider all ages from the youngest person given the implant up to and including those given the implant aged 17. For the answer to this question, a table like this may help illustrate the information I am asking for:
•
Age 9 10 11 12 13 14 etc up to 17
2021
2022
2023
2024
2025 so far

I look forward to a response within 20 working days. Please contact me on this email address if you have any queries.

Dear FOI Officer,

I am writing to request information under the Freedom of Information Act 2000.
Please could you provide the following information:

1. 1. The total number of recorded incidents of slips, trips, and falls in home bathrooms involving patients within your Trust/Health Board for each calendar year from 2020 to September 2025.

2. 2.If available, a breakdown of these figures by:

a. Age groups (50–59, 60–69, 70–79, 80–99, 100+)
b. Gender (Male, Female)

If any part of this request is unclear or would exceed the cost limit, please provide advice and assistance as required by Section 16 of the FOI Act.

I look forward to your response within the statutory 20 working days.

Please provide the data in an electronic format if possible.

Best wishes,

Dear the Gloucestershire Health and Care NHS Foundation Trust,

I hope you are well.

I’m a reporter for the Colchester Gazette and Newsquest.

I am writing to request information under the Freedom of Information Act 2000. I would like to obtain the following information:
• The number of miscarried babies that were reported as discarded, lost, or contaminated in the Gloucestershire Health and Care NHS Foundation Trust for the past five years.
• A breakdown of these incidents by year
• A breakdown of any costs due to these incidents
• A breakdown of hours spent by NHS workers either attempting to find or reporting or spending time on these incidents

This FOI follows this article https://www.gazette-news.co.uk/news/25393764.essex-womans-miscarried-baby-lost-hospital-contaminated/.

Please provide this information in an electronic format. If this request is too broad or unclear, I would be grateful if you could contact me to provide advice and assistance on how to refine it.

I am also contacting other NHS trusts across the United Kingdom.

Thank you for your time and assistance.

Dear Gloucestershire Health and Care NHS Foundation Trust,

I am writing to request the following information under the Freedom of Information Act.

The total number of Respiratory Physiology – Sleep Studies (10) performed in each of the respective financial years 2019/20, 2020/21, 2021/22, 2022/23, and 2023/24.

If the full dataset is not available, please supply the information you hold and advise how I might obtain the remainder.

We’re looking to conduct FOI requests with NHS trusts regarding prescriptions issued for sleep medications in the UK. For example, how many prescriptions were issued for sleep medications (e.g. Zopiclone, melatonin) in the last 5 years
• Total number of sleep disorders recorded in the last five years (broken down by year) and split by age range – I have attached a spreadsheet with the full list.
• The total number of drug prescriptions issued for the following sleep disorders in the past five years (broken down by year and by drug type e.g. Melatonin, Benzodiazepines, Z-drugs)
• The total number of patients referred to non-drug treatments, such as CBT-I

Please could you provide the following information: General Information

1. The total number of radiology scans performed at NHS hospitals in the last 12 months, broken down by modality (CT, MRI, and nuclear medicine scans).
2. A detailed breakdown of the scans performed by body part for each of the above modalities (For example CT head, MRI Spine, bone scan etc) at each trust.
3. The total number of outsourced scans for reporting purposes, categorized by modality (CT, MRI, and nuclear medicine) for each hospital / trust. Outsourcing and Teleradiology
4. Whether any radiology scans are outsourced to external providers by the hospitals.
5. The percentage of scans outsourced for each modality, if applicable at each hospital.
6. The names of the external providers contracted for outsourced radiology reporting to each NSH hospital.
7. The cost per scan for outsourced services, broken down by modality and body part. Financial Information
8. The total expenditure on outsourced radiology reporting services in the last financial year per trust.
9. Whether there are fixed pricing agreements between teleradiology providers and the hospitals, and if so, the details of these agreements to include start and finish dates and the cost in pounds. Contracts and Agreements
10. Any active contracts the hospitals have with teleradiology companies, including: a. The names of the contracted providers. b. The start and end dates of the contracts. c. The performance or quality metrics outlined in the contracts. Backlogs and Reporting Times
11. The current backlog for radiology scan reporting, broken down by modality and body part at each NHS trust.
12. The average reporting time for in-house radiology scans, categorized by modality.
13. The average reporting time for outsourced scans.
14. Whether specific modalities or body parts have more significant backlogs. Additional Details
15. Any delays in reporting radiology scans over the last 12 months and the primary causes of such delays.
16. Whether the hospital has plans to reduce reliance on outsourcing for radiology reporting, and if so, the details of these strategies.

Dear Sir/Madam,

I am writing under the Freedom of Information Act to make a request for information on the use of electroconvulsive therapy (ECT).

The information being requested is as follows:

1. Please provide the number of ECT treatments given to patients in the year 2025 to date (with the date range this applies to)

2. Please provide the number of patients having received ECT treatment in the year 2025 to date (with the date range this applies to)

I look forward to hearing from you in due course.

Good afternoon,
After extensive research, we have been unable to find the following data, and I would now like to request it from you.
Please can I request the number of CT scans referred from primary care for SCITID 12295008 Bronchiectasis, and if you have open access to CT scans from primary care.
Best wishes,

To whom it may concern, I am writing to you under the Freedom of Information Act 2000 on behalf of Myeloma UK to request the following information: 1. Is your health trust currently treating myeloma patients 2. Please list the hospitals in your board/trust that are currently treating myeloma patients. 3. Please list how many myeloma patients are being treated by your board/trust. Please break this down by hospital. 4. Is your health trust currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital. 5. Please list how many people have been given a) elranatamab or b) teclistamab since approval by the National Institute of Health and Care Excellence in 2024 (TA1023 and TA1015. If possible, please break this down by hospital. 6. Do you have a service level agreement or referral system in place with any other health trusts to deliver a) elranatamab or b) teclistamab to patients. If the answer this question is yes, which health boards / trusts do you have an agreement in place with. If you have any queries, please don’t hesitate to contact me via e-mail. Thank you for your time and I look forward to your response.

I keen to understand how much use the Acute Trust specialists are able to make of the Outpatient clinic facilities in Gloucestershire’s Community Hospitals. I am particularly interested in to know what Acute Trust services are provided at Moreton Community Hospital, although the question is also relevant to all of Gloucestershire’s Community Hospitals.

I believe that prior to the Pandemic good use of Moreton’s clinic space by Acute Trust Consultants etc was made, but that now clinics are few and far between – physio, orthoptists, hearing aid support. Your website suggests that clinics are held in response to demand. What constitutes “demand”?
Given the Secretary of State’s wish to move more specialist provision into the community, it would be helpful to know to what extent that already happens in our Community Hospitals, and what are the issues that prevent greater use. I guess that cost is a major block to greater use – but who bears what cost (GHC? GHT? ICB?)

As background, I am a retired GP and am currently a Public Governor at Gloucestershire Hospitals Trust. This issue has recently been raised with me by PPG members from North Cotswolds GP Practices. Residents in that area have long journey times to and from GRH or CGH, and are increasingly frustrated that OP clinics appear not to be held in the excellent facility at Moreton and elsewhere. I have family living in North Cotswolds too and understand their frustrations.

Would it be possible to provide me with a timetable of current use of Moreton clinic space, or would that need to go through FOI channels?

Please provide the following information, broken down by month, between January 2020 and July 2025 inclusive. If this is not possible, please instead provide it broken down by calendar year, 2020 to 2025 inclusive.

1. The number of times a patient was admitted where exposure to air pollution (International Classification of Diseases, tenth revision (ICD-10) code Z581)* was recorded as a contributing factor to the admission.
(* I understand this is the code used by NHS trusts to log exposure to air pollution, but if your trust uses a different code or some other system, please still provide the relevant data)

1a. If possible, please tell me what the primary diagnosis was for each of these admissions.
(For clarity, I want to know total numbers admitted with each primary diagnosis — for example, if 45 people were admitted with a primary diagnosis of asthma where exposure to air pollution was identified as a contributing factor.)

2. Please tell me how many of the patients in question 1 subsequently died in hospital.

If it is not possible to provide the information requested due to the information exceeding the cost of compliance limits identified in Section 12, please provide advice and assistance, under the Section 16 obligations of the Act, as to how I can refine my request.

If you can identify any ways that my request could be refined I would be grateful for any further advice and assistance.

If you are able to supply some of this information more quickly than other items, please supply each item when you can rather than delay everything until it is all available.

I’d like to make the following request under the freedom of information act.
Could you tell me, for 2019-2025
a) how many patients were transferred out-of-area
b) the furthest distance a patient was transferred
c) the longest period a patient was placed in an out-of-area trust

Dear colleagues,

We are undertaking a survey regarding the management pathway of elderly patients (>65 years old) presenting with trauma in the Emergency Department.

I am emailing you to a make freedom of information request with regard to trauma protocols for silver trauma patients. We would like to know the following information if available:

. Does your hospital have a guideline for silver trauma patients (>65 years old) attending ED?

. What are the ED’s indications for initiating a silver trauma call and requesting a trauma CT for elderly patients at your hospital?

· Which specialties are called for silver trauma in ED? Does it include General surgery, Orthopaedics, Anaesthetics and Medicine of the elderly?

· Does your hospital have a guideline for assessing delirium in silver trauma patients (>65 years old)?

· Do all the silver trauma patients get reviewed by medicine of the elderly on the ward if admitted? · Do you have a guideline for assessment of the silver trauma patients on the ward by medicine of the elderly?

· Can you please attach your hospital’s guidelines for silver trauma patients in your reply?

Thank you for your help! Looking forward to your response.

Please do not include any patient confidential information in your response.

Dear FOI Officer, I am writing to request information, under the Freedom of Information Act 2000, regarding carbon monoxide (CO) cases in relation to research for Project SHOUT.

Could you please provide the following information, from the Gloucestershire Health and Care NHS Foundation Trust, for the periods: 1st August 2018 to 31st July 2019:

• The total number of carbon monoxide (CO) cases that attended A&E

1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over

• The total number of carbon monoxide (CO) cases that were treated at A&E

1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over 1st August 2019 to 31st July 2020:

• The total number of carbon monoxide (CO) cases that attended A&E

1. Of the total figure, how many were aged 0-18 years old 2.

Of the total figure, how many were aged 60 years old and over

• The total number of carbon monoxide (CO) cases that were treated at A&E

1. Of the total figure, how many were aged 0-18 years old

2. Of the total figure, how many were aged 60 years old and over 1st August 2020 to 31st July 2021:

• The total number of carbon monoxide (CO) cases that attended A&E

1. Of the total figure, how many were aged 0-18 years old

2. Of the total figure, how many were aged 60 years old and over

• The total number of carbon monoxide (CO) cases that were treated at A&E

1. Of the total figure, how many were aged 0-18 years old

2. Of the total figure, how many were aged 60 years old and over 1st August 2021 to 31st July 2022:

• The total number of carbon monoxide (CO) cases that attended A&E

1. Of the total figure, how many were aged 0-18 years old

2. Of the total figure, how many were aged 60 years old and over

• The total number of carbon monoxide (CO) cases that were treated at A&E

1. Of the total figure, how many were aged 0-18 years old

2. Of the total figure, how many were aged 60 years old and over 1st August 2022 to 31st July 2023:

• The total number of carbon monoxide (CO) cases that attended A&E

1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over

• The total number of carbon monoxide (CO) cases that were treated at A&E

1. Of the total figure, how many were aged 0-18 years old

2. Of the total figure, how many were aged 60 years old and over 1st August 2023 to 31st July 2024:

• The total number of carbon monoxide (CO) cases that attended A&E

1. Of the total figure, how many were aged 0-18 years old

2. Of the total figure, how many were aged 60 years old and over

• The total number of carbon monoxide (CO) cases that were treated at A&E

1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over 1st August 2024 to 31st July 2025:

• The total number of carbon monoxide (CO) cases that attended A&E

1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over

• The total number of carbon monoxide (CO) cases that were treated at A&E

1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over If possible.

I would be grateful to receive this information in an Excel spreadsheet format.

Under the Freedom of Information Act 2000 I would like to request the following information.

This request relates to NHSE’s July 2025 time-series elective care waiting list release from September 2021-June 2025 which disaggregated data by age and sex and partially disaggregated by ethnicity and Indexes of Multiple Deprivation (IMD). Please provide the requested information in an Excel spreadsheet.

1. Share the paediatric elective care waiting list data (under 18) disaggregated by ethnicity and IMD for the time-series September 2021-June 2025, displayed as total numbers waiting month by month. Please indicate if this data has not been collected.

2. Share paediatric community service waiting list data (under 18) disaggregated by ethnicity and IMD for the time-series September 2021– June 2025, displayed as total numbers waiting month by month. If this data has not been collected, please provide the total waiting list for paediatric community care between September 2021-June 2025 by month.

If it is not possible to provide the information requested due to the information exceeding the cost of compliance limits identified in Section 12, please provide advice and assistance, under the Section 16 obligations of the Act, as to how I can refine my request.

If you have any queries, please don’t hesitate to contact me via email and I will be happy to clarify. Thank you for your time and I look forward to your response.

Hi. Thank you for responding to the FOI below. I have a few follow up questions.

1. How many patients have had TMS funded by GHC in the last 24 months.

2. Could you give an estimate on total expenditure on TMS in last 24 months.

3. What providers (NHS or private) have delivered TMS funded by GHC.

I am writing to submit a request for information under the Freedom of Information Act 2000.

I would be grateful if you could provide information regarding your hospitals clinical practice on the timing of methotrexate (MTX) level monitoring in patients receiving high-dose methotrexate (HDMTX) therapy. Specifically, I am seeking the following:

Adult Patients
1. For adult patients with acute lymphoblastic leukaemia (ALL) receiving HDMTX, at what time point does your centre take the first MTX level?
2. For adult patients with osteosarcoma receiving HDMTX, at what time point does your centre take the first MTX level?
3. For adult patients with non-Hodgkin’s lymphoma receiving HDMTX, at what time point does your centre take the first MTX level?

Paediatric Patients
1. For paediatric patients with acute lymphoblastic leukaemia (ALL) receiving HDMTX, at what time point does your centre take the first MTX level?
2. For paediatric patients with osteosarcoma receiving HDMTX, at what time point does your centre take the first MTX level?
3. For paediatric patients with non-Hodgkin’s lymphoma receiving HDMTX, at what time point does your centre take the first MTX level?

Please note that I am not requesting any patient-specific data. This request relates solely to your clinical practice guidelines or standard protocols.

Please can you tell me:

1. The number of patients who have died while on your waiting list to recieve consultant-led elective (planned) hospital treatment — and who have therefore been removed from the list due to to their death or status as being deceased — between January 1 2025 and July 31 2025?
(If your trust calls this particular waiting list something else, please use common sense and provide the waiting list data most relevant to my questions.)

1a. If possible, please tell me how many of these people who died had been waiting for longer than 18 weeks since being referred for consultant-led elective hospital treatment?

1b. If possible, please provide a seperate breakdown of the ethnicity and religion of all those who died while on this your waiting list to recieve consultant-led elective (planned) hospital treatment over this time period.

2. The number of patients who have died while on your waiting list to recieve consultant-led elective (planned) hospital treatment — and who have therefore been removed from the list due to to their death or status as being deceased — broken down into the years 2024, 2023, 2022, 2021 and 2020, please.

2a. If possible, please provide a seperate breakdown of the ethnicity and religion of those who died while on you waiting list for consultant-led elective (planned) hospital treatment in each of these years.

If you are encountering any practical difficulties with complying with this request, please contact me as soon as possible (in line with your duty under section 16 to advise and assist requesters), so that we can discuss the matter and if necessary I can modify the request.

If you are able to supply some of this information more quickly than other items, please supply each item when you can rather than delay everything until it is all available.

Please format this data clearly and provide it in a machine readable format (such as xslx).

I have attached a Freedom of Information request regarding your PROSTHETIC and/or ORTHOTIC services.

I would like to submit an FOI request for the following data for Gloucestershire Health and Care NHS Foundation Trust:
1. The number of unique patients with a recorded diagnosis of Dravet syndrome in 2024-2025. Likely coded as ICD-10 code G40.3 or SNOMED code of 230437002, ideally separated by month.
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
2. The number of unique patients with a recorded diagnosis of Lennox-Gastaut syndrome in 2024-2025. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006, ideally separated by month.
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
3. The number of unique patients who have been treated with fenfluramine in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside fenfluramine, and indicate the number of patients receiving each
4. The number of unique patients who have been treated with cannabidiol in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside cannabidiol, and indicate the number of patients receiving each
5. The number of unique patients who have been treated with cenobamate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside cenobamate, and indicate the number of patients receiving each
6. The number of unique patients who have been treated with rufinamide in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside rufinamide, and indicate the number of patients receiving each
7. The number of unique patients who have been treated with stiripentol in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside stiripentol, and indicate the number of patients receiving each
8. The number of unique patients who have been treated with clobazam in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside clobazam, and indicate the number of patients receiving each
9. The number of unique patients who have been treated with sodium valproate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside sodium valproate, and indicate the number of patients receiving each
10. The number of unique patients who have been treated with levetiracetam in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside levetiracetam, and indicate the number of patients receiving each
11. The number of unique patients who have been treated with topiramate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside topiramate, and indicate the number of patients receiving each
12. The number of unique patients who have been treated with lamotrigine in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
8 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside lamotrigine, and indicate the number of patients receiving each

Under the Freedom of Information Act 2000, I would like to request information regarding clinical documentation practices, specifically in relation to the capture of information during interventional procedures, such as Central Venous Access Device (CVAD) insertions.

1. Clinical Documentation
• What methods are currently used by clinicians to document key information during invasive procedures, such as CVAD insertions (e.g., paper forms, digital forms, voice dictation, other)?
o Is any form of structured digital data entry used at the point of care for these procedures?
• Are standardised templates or proformas used Trust-wide for documenting invasive procedures, such as Local Safety Standards for Invasive Procedures (LocSSIPs)?
o Are any of these LocSSIPs or other forms digitised?

2. Voice Technology
• Does the Trust currently use any voice-to-text or voice recognition technology for clinical documentation (e.g., Dragon Medical One, Nuance, Voice-Care, etc.)?
• If yes, which departments or specialties currently use it, and for which types of documentation?

3. Administrative Efficiency
• Has the Trust undertaken any assessments of the administrative time burden associated with completing procedural documentation (manual or digital)?
o If so, is any information available on time spent per procedure or efforts to streamline the process?

4. Future Plans
• Is the Trust currently planning any initiatives or procurements to digitise documentation processes for interventional procedures?
o If yes, please outline the scope and timelines if available.

I am writing under the Freedom of Information Act 2000 to request information relating to the diagnosis and treatment of hip fractures for patients presenting at your Minor Injuries department, broken down by year, for the past four calendar years (2021, 2022, 2023, 2024) up to and including 03 May 2025:

· The number of patients who presented at Minor Injuries with hip pain and were referred for: X-Ray o MRI scan.

· Of those who underwent an X-ray only, how many had negative or inconclusive results but were later diagnosed with a femoral neck or other hip fracture?

If the request exceeds the cost exemption, as per s12 of the 2000 Act, please advise me on how to amend my request accordingly.

I am submitting this request under the Freedom of Information Act 2000. Please provide the following information:

1. Longest wait times for therapy services. Please provide the longest recorded wait times for local NHS Talking Therapies in 2024.
2. Percentage of patients waiting more than 90 days for their first completed appointment.
3. Repeat referrals within 12 months of discharge. Please provide the number of patients who were discharged from local NHS Talking Therapies but required a repeat referral within 12 months in 2024.
4. Total referrals for local NHS Talking Therapies in the 2024 calendar year.
In the event you can’t respond to all four questions please answer as many as possible taking each in turn, 1-4.

I would be grateful if you could please answer the following question with regards to cancer treatment:

In the last 12 months, how many unique patients in your trust have been treated privately for the following ICD-10 codes?

A) C61 Malignant neoplasm of prostate
B) C16.0 Malignant neoplasm of the gastroesophageal Junction

I am writing to request the following information under the Freedom of Information Act:

For the period from January 2019 to the most recent available data, please provide the following details relating to admissions involving the insertion of objects into the anus or vagina.

• The total number of incidents recorded per year.
• The age and gender of the individual involved in each incident (if available and anonymised).
• A brief description of the incident or nature of injury and if the insertion was accidental or deliberate (if available and anonymised).
• The item used – including but not limited to sex toys, household objects, and food.

I am conducting a research project to compare the safety and efficacy of permanent versus absorbable sutures in Colposuspension for the management of stress urinary incontinence in women. I would be grateful if you could help me with this data.

From your hospital surgical database, please can you provide us with:
1. the number of Colposuspensions conducted in your unit between January 2020 and January 2025.
Of these, please clarify how many were conducted:
-open
-laparoscopically
-robotically

2. How many of these cases have needed to go back to theatre for any procedure under the care of urogynaecology/gynaecology/urology since the initial operation?
Please state, what procedures they then underwent.

The following questions, may be known by the theatre team via the surgeon’s cardex (information sheet which each surgeon will have with their preference of equipment for each operation) for Colposuspension. In the worst case, it may need to posed to the surgeons who usually perform colposuspensions but should be a quick answer:

“Which suture material is routinely used to suture onto the iliopectineal ligament in open cases? Please state name of suture or N/A if this route of colposuspension is not performed.”

“Which suture material is routinely used to suture onto the iliopectineal ligament in laparoscopic cases? Please state name of suture or N/A if this route of colposuspension is not performed.”

“Which suture material is routinely used to suture onto the iliopectineal ligament in robotic cases? Please state name of suture or N/A if this route of colposuspension is not performed.”